RxDoctor Payments Data

Timothy Henry, MD

Interventional Cardiology · Cincinnati, OHNPI 1114987997

Payments from drug & device makers

What this record shows

This record is dominated by consulting fees: $494,552 of the $605,206 with a category attached, or 81.7%. 41 manufacturers reported payments, led by Neovasc Medical Inc at 42.3% of the total. Among interventional cardiology clinicians in OH with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$605,206in general payments, 2019–2025

Across 401 payments — averaging $1509.24 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Neovasc Medical Inc$256K
  • Shockwave Medical, Inc$170K
  • Abbott$52K
  • Amgen$27K
  • Kiniksa Pharmaceuticals, Ltd.$26K
  • ZOLL Circulation Inc$12K
  • plus $63K from 35 others
$689,302in research payments, 2019–2025

Across 50 payments — averaging $13,786 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Shockwave Medical, Inc$353K
  • Amgen$189K
  • Neovasc Medical Inc$68K
  • Gentuity, LLC$41K
  • Gilead$25K
  • Atricure, Inc.$11K
  • plus $3K from 1 others

What the payments were for

  • Consulting fees$494,55282%
  • Speaking & faculty fees$84,67914%
  • Travel & lodging$9,6742%
  • Food & beverage$16,2963%
  • Education$50%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$605,206 in reported general payments places this provider in the 95th percentile of 256 interventional cardiology providers in Ohio.

See all interventional cardiology providers in Ohio

Medicare billing

Part B allowed, 2024
$48,819
Medicare patients
163
Services billed
391

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Repatha SureclickEvolocumab92$104,301
EliquisApixaban39$51,687
Praluent PenAlirocumab24$33,753
EntrestoSacubitril/Valsartan14$30,962
Ranolazine ErRanolazine68$9,406
Atorvastatin Calcium200$1,983
ClopidogrelClopidogrel Bisulfate135$1,741
Rosuvastatin Calcium103$1,416
Metoprolol Succinate68$1,225
Losartan Potassium146$1,207
Nitroglycerin56$968
Isosorbide Mononitrate ErIsosorbide Mononitrate75$827
Ezetimibe40$773
Amlodipine Besylate153$758
Nitroglycerin PatchNitroglycerin13$487

Paid to pharmacies, not to this prescriber.

Other interventional cardiology in Cincinnati

See the full list for Ohio

Where these figures come from

Is this you, or does something look wrong? →